Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) announced that Malte Peters, M.D., President and CEO, will appear in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The event will be webcast live and a replay will be archived on the company website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – TNGX
In the Feb 3 session, TNGX gained 5.11%, reflecting a notable positive market reaction. Argus tracked a peak move of +16.3% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | CEO transition | Neutral | -6.2% | Founding CEO retires; Malte Peters becomes President and CEO. |
| Jan 05 | Board appointment | Positive | -0.2% | Experienced finance executive Sung Lee joins the board. |
| Dec 17 | Conference participation | Neutral | -2.0% | Corporate presentation at J.P. Morgan Healthcare Conference announced. |
| Nov 26 | Conference participation | Neutral | +1.8% | Piper Sandler healthcare conference fireside chat participation disclosed. |
| Nov 12 | Conference participation | Neutral | -8.5% | Jefferies Global Healthcare Conference fireside chat participation announced. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent leadership and conference announcements often saw negative next-day moves, with only one of the last five events showing a positive 24-hour reaction.
Over the last few months, Tango reported leadership changes, board strengthening, and multiple healthcare conference appearances. The CEO transition on Jan 8, 2026 coincided with a -6.23% move, while prior conference participations around Jefferies, Piper Sandler, and J.P. Morgan produced mixed single-day reactions ranging from -8.47% to +1.8%. Today’s announcement of participation in another investor-focused biotech summit continues this pattern of non-clinical, investor-relations oriented updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
